May 18, 2021Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA) on Iodixanol Injection.view
December 1, 2023The flagship product, Jiuwei Zhenxin Granules, a central nervous system medication developed by Beilu Pharmaceutical, has been included in the "Guidelines for the Diagnosis and Treatment of Ankyl...view
July 11, 2024Recently, Beilu Pharmaceuticals received the Drug Registration Certificate for Gadopentetate Dimeglumine Injection and the approval notice for the marketing application of Gadopentetate Dimeglumine as...view
November 30, 2021Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...view
June 8, 2023Recently, the Beijing Municipal Drug Administration and the Beijing Municipal Health Commission issued a notification on "Commending Outstanding Units and Individuals in the Monitoring of Adverse...view